Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 652-657, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparison of Two Recombinant Major Outer Membrane Proteins
of the Human Granulocytic Ehrlichiosis Agent for Use in an
Enzyme-Linked Immunosorbent Assay
Tomoko
Tajima,1
Ning
Zhi,1
Quan
Lin,1
Yasuko
Rikihisa,1,*
Harold W.
Horowitz,2
John
Ralfalli,2
Gary P.
Wormser,2 and
Karim E.
Hechemy3
Department of Veterinary Biosciences, College of Veterinary
Medicine, The Ohio State University, Columbus, Ohio
43210-10931; Division of Infectious
Diseases, Department of Medicine, New York Medical College, Valhalla,
New York 105952; and Wadsworth
Center, New York State Department of Health, Albany, New York
12201-05093
Received 15 November 1999/Returned for modification 13 March
2000/Accepted 8 May 2000
 |
ABSTRACT |
Enzyme-linked immunosorbent assay (ELISA) for human granulocytic
ehrlichiosis (HGE) using two different recombinant P44 proteins (rP44
and rP44-2hv) of the HGE agent as antigens was evaluated. Sera from a
total of 72 healthy humans both from regions where HGE is nonendemic
and regions where HGE is endemic were used as negative controls to
determine the cutoff value for ELISA. Sera from a total of 14 patients
(nine from whom the HGE agent was isolated and five who were HGE-PCR
positive) were used as positive controls. One hundred nine sera from 72 patients in an area where HGE is endemic who were suspected of having
HGE were examined by ELISA and indirect immunofluorescence assay (IFA).
All IFA-negative sera were negative by both ELISAs. Of 39 sera that
were IFA positive, 35 and 27 were positive by ELISA using rP44 and
rP44-2hv, respectively, indicating that the use of rP44 is more
sensitive. Western blot analysis of the four rP44-ELISA-negative
IFA-positive sera using whole HGE agent as antigen suggests that these
four sera were false IFA positive. There was no difference in results
with or without the preabsorption of sera with Escherichia
coli or with or without the cleavage of the fused protein derived
from the vector. There was a significant positive correlation between
IFA titers and optical densities of ELISAs. Four Ehrlichia
chaffeensis-positive and 10 Borrelia
burgdorferi-positive sera were negative by ELISA. However, two
Babesia microti-positive sera showed strong
cross-reactivity to the fused vector protein, which was eliminated
after cleavage of the protein. Thus, ELISA using rP44 nonfusion protein
would provide a simple, specific, and objective HGE serologic test
which can be easily automated.
 |
INTRODUCTION |
Human granulocytic ehrlichiosis
(HGE) was first reported in 1994 from Wisconsin and Minnesota (2,
5) and subsequently from other areas of the United States
(1, 9, 32, 36) and Europe (17, 25, 34). The
etiologic agent of HGE is an obligatory intracellular bacterium that
belongs to the Ehrlichia equi- Ehrlichia phagocytophila
group on the basis of 16S rRNA gene sequence comparison (5)
and serological cross-reactivity (8). Development of a
specific, sensitive, and rapid diagnostic method to distinguish HGE
from other tick-borne infections is desirable to ensure appropriate
antimicrobial therapy, because Ixodes spp. are the vector
for the HGE agent, Borrelia burgdorferi, and Babesia
microti and the coexistence of the latter two pathogens and the
HGE agent in ticks has been demonstrated by using PCR (24, 28, 29,
35). Serologic data suggest human exposure to all three agents in
Connecticut, Minnesota, and Wisconsin (18-20), and HGE and
Lyme borreliosis have simultaneously been reported (7, 21).
At present, there is no single "gold standard" for the diagnosis of
HGE. Culture isolation, PCR, and serology each have strengths and
weaknesses. Positive results in culture isolation or PCR tests are
definitive, but negative results in culture isolation or PCR are not
definitive. Negative indirect immunofluorescence assay (IFA) results
with samples tested at both acute and convalescent stages may be
definitive (if samples are not from immunocompromised individuals and
antibiotic treatment is not initiated too early), but positive IFA
results may not be definitive because of the subjective nature of
evaluation and occasional cross-reactivity with other antigens.
Comparison of sensitivity and specificity is, therefore, meaningful
when compared among the same type of assay, such as serology, but not
when compared between different types of tests. IFA using HGE agent- or
E. equi-infected cells as antigen is currently the most
widely used method for diagnosis of HGE (3, 6, 22). Although
IFA is sensitive and simple, it has several problems. Since the HGE
agent is an obligatory intracellular bacterium, it is necessary to
culture the HGE agent in eukaryotic host cells to prepare infected-cell
antigen. Culturing is labor-intensive and produces batch-to-batch
variation in antigens. Furthermore, the use of whole infected cells as
antigen may increase the false-positive rate due to antigenic
cross-reactivity. The visual evaluation of test results precludes rapid
testing of a large number of samples, and the subjective evaluation of
test results may cause variation in titers among different laboratories and technical personnel. Moreover, the cutoff titers for positive IFA
reactions differ among laboratories, ranging from 20 to 80 (3, 4,
6, 21, 34, 37, 38).
Enzyme-linked immunosorbent assay (ELISA) is desirable for automated
testing of large numbers of serum samples. Ravyn et al. (26)
reported that an ELISA using native HGE agent cultured in HL-60 cells
as antigen is more sensitive than IFA. However, some samples are ELISA
positive but Western blot negative. They recommended a two-test method
of screening by ELISA and confirmation of specificity by Western blot
analysis (26). Recently, an ELISA for HGE using a
recombinant surface 44-kDa protein (HGE-44) of the HGE agent (NCH-1
strain isolated from a patient in Massachusetts) fused with maltose
binding protein was reported (total molecular mass of approximately 80 kDa) (12). We previously demonstrated that a dot blot assay
using the recombinant major surface 44-kDa protein P44 (rP44) of the
HGE agent (strain no. 13, isolated from a patient in New York) is
useful for serodiagnosis of HGE (39). Further molecular
analysis revealed that among approximately 20 P44 proteins of the
multigene family, P44-2 is most abundantly expressed by the HGE agent
in HL-60 cell culture, and HGE patients' sera reacted with a synthetic
peptide specific to P44-2 (40). In the present paper, we
compare the usefulness of our rP44 and the recombinant P44-2
hypervariable region (rP44-2hv) as antigen with ELISAs using various
sera, including B. microti antibody-positive sera, and
investigated the need for either Escherichia coli
preabsorption of sera or cleavage of fused vector peptide from the
fusion protein.
 |
MATERIALS AND METHODS |
Sera.
A total of 109 sera were collected from 72 patients at
Westchester Medical Center in New York State from June 1995 to
September 1997 who were suspected of having HGE based on clinical signs and exposure to ticks. Sera were collected once from 45 patients, twice
from 17 patients, and three times from 10 patients, with more than 4 days between collection days. Convalescent-phase sera from nine
patients from whom the HGE agent was isolated and five sera from
patients who were HGE-PCR positive were used as positive controls
(11, 38). Nested PCR as described by Chen et al. (5) and Sumner et al. (31) was used to detect the
HGE agent DNA in blood specimens. Sera from 20 healthy humans from
Westchester, New York, and sera from 53 healthy humans in Japan, kindly
provided by Makoto Kawahara, Nagoya City Public Health Research
Institute (Nagoya, Japan), were used as negative controls. HGE is
endemic in Westchester but has not yet been identified in Japan. Ten
sera, which were demonstrated to be seropositive by ELISA and Western blotting analysis for B. burgdorferi (10), were
also tested in the present study. Two sera from B. microti-infected patients were supplied by Lily I. Kong, MRL
Diagnostic Laboratory (Cypress, Calif.). Five sera, positive for
antibodies against Ehrlichia chaffeensis by IFA and Western
immunoblotting (33), were provided by MRL Diagnostic Laboratory.
IFA.
IFA was performed as previously described
(27). Briefly, the HGE agent (isolate no. 13, referred to as
New York isolate [27]) was cultured in the human
promyelocytic leukemia cell line HL-60. Heavily infected (>80%
infected) cultures of cells were suspended in RPMI 1640 medium and were
dispensed onto 12-well slides at a concentration of 104
cells/well. A twofold serial dilution of test sera starting at 1:20 was
prepared in 2× phosphate-buffered saline (PBS; 19 mM Na2HPO4, 12 mM NaH2PO4,
300 mM NaCl, pH 7.4). Ten microliters of each dilution of the serum was
reacted with antigen at 37°C for 1 h. After washing, the slides
were reacted with 10 µl of fluorescein isothiocyanate-conjugated goat
anti-human immunoglobulin G (IgG) (Organon Technika, Westchester, Pa.)
at a dilution of 1:200. After incubation at 37°C for 1 h, the
slides were washed, counterstained with Evans blue (Sigma, St. Louis,
Mo.), and examined under the epifluorescent microscope. The serum
antibody titer was expressed as the reciprocal of the highest dilution
of serum that showed a positive reaction. Serum that had an antibody
titer greater than 1:20 was considered positive because all the sera from healthy individuals used in this study, except one false-positive serum, were IFA negative at a serum dilution of 1:20.
rP44 and rP44-2hv antigen.
E. coli BL21(DE3)/pLysS
(Novagen, Inc., Madison, Wis.) transformed with pEP44, the recombinant
pET30a vector (39), was cultured, and rP44 protein was
purified by using His-Bind Resin (Novagen) as previously described
(39).
To express P44-2hv, the primers were designed to amplify the DNA
sequence encoding a 153-amino-acid sequence of the hypervariable region
of the P44-2 from the 138th to the 283th amino acid (GenBank number
AF135254) (40). The 5' oligonucleotide primer consists of
the p44-2 gene sequence from positions 416 to 437 (AF135254) and a NcoI restriction site (underlined)
(5'-GGCCATGGAGTTAGCTTATGATGTTGT-3'), and the 3'
oligonucleotide primer consists of the p44-2 gene sequence from
positions 832 to 849 with a stop codon (TAA [in boldface]) and an
EcoRI restriction site (underlined)
(5'-GCGAATTCTTAAGGGGTTAGCTCCTG-3'). The PCR
amplification was carried out with a Perkin-Elmer Cetus DNA thermal
cycler (model 480) by using standard procedures. The 459-bp amplified
product was digested with NocI and EcoRI and was
ligated into dephosphorylated NocI- and
EcoRI-digested pET30a expression vector. The recombinant
plasmid was designated pET30a-p44-2-3. E. coli NovaBlue
(Novagen) was transformed with the recombinant pET30a. A plasmid
preparation of pET30a-p44-2-3 from transformed NovaBlue was then used
to transform E. coli BL21. The recombinant protein was named
rP44-2hv. The induction of the recombinant protein was performed by a
procedure described elsewhere (39).
To remove the fused protein derived from the vector, enterokinase
treatment was carried out using recombinant enterokinase (EK) kit
(Novagen). Fifty micrograms of rP44 or rP44-2hv was mixed with 1 U of
EK in the cleavage-capture buffer (20 mM Tris-HCl, 50 mM NaCl, 2 mM
CaCl2, pH 7.4) and was reacted for 16 h at room temperature. After the cleavage reaction, the mixture was incubated with Ekapture Agarose to remove excess EK. The cleaved rP44 (EK-rP44) and rP44-2hv (EK-rP44-2hv) were collected by centrifugation by using
spin filters (Novagen) and were stored at
80°C until use.
ELISA.
A 2-µg/ml concentration of each recombinant antigen
was used in the present experiment. Fifty microliters of recombinant
antigen diluted with 0.05 M carbonate buffer (pH 9.6) was absorbed onto individual wells of Coster 96-well enzyme immunoassay-radioimmunoassay plates (Corning, N.Y.) and was left overnight at 4°C in a humidified box. Excess antigen solution was removed, and the wells were then coated with 100 µl of 5% nonfat dried milk (Kroger, Cincinnati, Ohio) in 2× PBS at 37°C for 1 h to block non-specific protein binding sites. Sera diluted 1:20 with 5% nonfat dried milk in 2× PBS,
with or without preabsorption with E. coli, were added to
respective wells (50 µl/well) and were incubated at 37°C for 1 h. A twofold serial dilution of positive control sera was prepared with
5% nonfat dried milk in 2× PBS and was reacted with EK-rP44 in the
same manner. After three washes with 0.05% Tween 20 in 2× PBS, 50 µl of a 1:1,000 dilution of peroxidase-conjugated goat anti-human IgG
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) was added to
each well and incubated at 37°C for 1 h. The wells were again
washed as described above, and 100 µl of a mixture of 0.2 mM
2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) and 0.004%
H2O2 in 0.006 M citric acid-0.008 M
Na2PO4 (pH 4.0) was added. After incubation at
room temperature for 20 min, 50 µl of 1 M
H2SO4 was added to stop the reaction, and the
optical density at 405 nm (OD405) was measured. The assay
was repeated three times for each sample with different batches of rP44
protein-coated plates, and the reproducibility was confirmed. The
antibody titer of positive control serum was expressed as the
reciprocal of the highest dilution of serum that showed a positive reaction.
Preabsorption of sera.
E. coli BL21(DE3)/pLysS
transformed with pET30a vector suspended in 2× PBS was disrupted by
sonication and dispensed to each well of a 96-well microplate (100 µl/well) and centrifuged at 400 × g for 15 min. The
supernatant was removed, sera diluted 1:20 with 2× PBS containing 5%
nonfat dried milk was added to each well, and the plate was incubated
at 37°C for 30 min and further incubated at 4°C overnight. Then,
the plate was centrifuged at 400 × g for 15 min, and
the supernatant was used in ELISA.
Western blotting analysis.
Sephacryl S-1000 column-purified
HGE agent (10 µg) (38) and rP44 protein (3 µg) separated
by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis were
transferred to a nitrocellulose membrane and immersed in Dulbecco's
PBS containing 5% nonfat dried milk at 4°C overnight to block
nonspecific reactions. The membrane was reacted with sera diluted 1:100
followed by incubation with peroxidase-conjugated goat anti-human IgG
at the dilution of 1:2,000. As a positive control, a mouse monoclonal
antibody against the 44-kDa protein of the HGE agent, 5C11
(16), and peroxidase-conjugated goat anti-mouse Igs (IgG,
IgA, and IgM) (ICN Pharmaceuticals, Aurora, Ohio) were used at
dilutions of 1:500 and 1:2,000, respectively. The peroxidase reaction
was carried out in 70 mM sodium acetate buffer (pH 6.2) containing
0.3% diaminobenzidine tetrahydrochloride (Nakarai Tesque, Inc., Kyoto,
Japan) and 0.03% H2O2, and the reaction was
stopped by washing the membrane in 0.1 M H2SO4.
Protein assay.
Protein concentration was measured by using
BCA Protein Assay Kit (Pierce, Rockford, Ill.) using bovine serum
albumin as standard.
Statistical analysis.
The data were analyzed by STATVIEW,
version 4, for Macintosh (Abacus Concepts, Berkeley, Calif.) to
determine Spearman's rank correlation coefficient.
 |
RESULTS |
Determination of the cutoff value in ELISA.
Sera from 20 healthy humans in the United States and 52 of 53 healthy humans in
Japan were IgG antibody negative (<1:20) by HGE-IFA. One IFA-positive
serum was further examined by Western immunoblot analysis as described
later. ELISA was independently performed three times for each
IFA-negative serum using EK-rP44, rP44, or EK-rP44-2hv as antigen. The
mean and standard deviation (SD) of OD405 of each sample
were calculated. Under the assumption of a normal (Gaussian)
distribution, the expected true negative rate is 99.9% if the cutoff
value selected is equal to the mean of the negative reference serum
plus three times the SD (15). When EK-rP44 was used as an
antigen, the mean absorbance of these negative sera was 0.142 and the
SD was 0.040. Therefore, the cutoff value was 0.262. When rP44 was used
as an antigen, the mean absorbance and SD were 0.143 and 0.033, respectively, and the cutoff value was 0.243. The mean absorbance and
SD were 0.074 and 0.020 for EK-rP44-2hv, and the cutoff value was
0.134.
ELISA using positive control sera.
Convalescent-phase sera
from 14 patients from whom HGE agent was isolated and/or who were
HGE-PCR positive (11, 38) were used as positive controls in
ELISA testing. The results from ELISA using EK-rP44 as an antigen are
summarized in Table 1. The tests were
independently repeated three times with ELISA plates coated with
different batches of recombinant antigen; in every test all the samples
were positive. The antibody titers were determined by IFA and ELISA
were similar. Coefficients of variation were calculated by dividing the
SDs of replicates by the means of replicates. A value of less than 20%
indicates adequate reproducibility (15). In the present
results, coefficients of variation of all samples were less than 20%,
indicating the adequate precision of this system. The results of ELISA
using rP44 or EK-rP44-2hv were similar (data not shown).
Reactivity of sera from patients positive for antibodies to
E. chaffeensis, B. burgdorferi, or B. microti.
To check cross-reactivity in ELISA, 4 E. chaffeensis-, 10 B. burgdorferi-, and 2 B. microti-positive sera were tested. Sera from B. microti-infected patients reacted with rP44 antigen in ELISA, and
OD405s were 0.858 and 0.786, respectively. However, these
reactivities disappeared after digestion of rP44 with EK, and the
OD405s reduced to 0.147 and 0.122, respectively. These sera
from B. microti-infected patients did not react with
EK-rP44-2hv antigen (OD405 < 0.139). None of E. chaffeensis- or B. burgdorferi-infected sera reacted
with rP44 antigen (OD405 < 0.243), EK-rP44
antigen (OD405 < 0.262), or EK-rP44-2hv antigen
(OD405 < 0.139).
ELISA of patient sera using EK-rP44 or rP44.
One hundred nine
sera from 72 patients suspected of having HGE were examined by ELISA
testing. All IFA-negative sera were negative by ELISA using EK-rP44 or
rP44. Of 39 IFA-positive (>1:20) sera, 35 from 21 patients were
positive by ELISA using EK-rP44 or rP44. To verify that an
ELISA-positive reaction was not against E. coli proteins
that may be present in the affinity-purified rP44 antigen preparation,
all patient sera were preabsorbed with E. coli transformed
with pET-30a expression vector in order to remove antibodies which
might be present and potentially react with E. coli
proteins, and the ELISA was repeated. The same results as obtained
without preabsorption of sera were obtained (data not shown). We,
therefore, conclude that the ELISA reactivity was against rP44, not
against E. coli proteins, and that preabsorption of sera
with E. coli is not required for this ELISA.
Reactivities of four IFA-positive but ELISA-negative patient sera were
examined by Western blot analysis by using the purified whole HGE agent
antigen. One additional serum from a healthy Japanese individual (N34),
which was IFA positive (1:320) but ELISA negative, was also included in
the analysis. The results are shown in Fig. 1 and Table
2. Two sera (serum ID.B66 and A19) from
patient P63 and one serum (serum ID.J14) from healthy human N34 reacted
only with an approximately 70-kDa protein of the purified HGE agent in
Western blotting analysis. One serum (serum ID.B20) from patient P24
reacted only with a single band of 44 kDa of the HGE agent even at the
serum dilution of 1:100. None of these four sera reacted with rP44 or
uninfected HL-60 cells in Western blotting analysis (data not shown).
All HGE patient sera (serum ID-A30 and B02 in Fig. 1) from
culture-positive or PCR-positive patients reacted not only with more
than two bands of approximately 44 kDa but also with proteins of other
sizes, as well as with rP44. Because patterns of the reactivity were
different from those of the positive control sera from HGE patients, we
conclude that these four sera from three individuals (N34, P24, and
P63) were not infected with the HGE agent.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Western blot analysis of patient sera by using the
native HGE agent as an antigen. Samples subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis consisted of 10 µg of
purified whole-cell preparation of HGE agent. The protein was
transferred to nitrocellulose membrane and was incubated with a 1:100
dilution of sera (B66, J14, B20, A30, B02, B14, MoAb, or J01). Numbers
at the left are molecular mass standards (in kilodaltons) based on the
broad-range prestained standards (Bio-Rad Laboratories, Richmond,
Calif.).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Results of IFA, ELISA, and Western blotting in sera from
three patients and one healthy human who were IFA positive but
ELISA negative
|
|
One serum (serum ID.B14), collected at 110 days after positive HGE
culture from patient P32, had an IFA titer of 80 but was negative by
either ELISA. This serum was the third sample collected from this
patient. The first acute-phase sample was antibody negative in both IFA
and ELISA. The second sample (serum ID.B27 in Table 1), collected 26 days after the first sampling, demonstrated an IFA titer of 2,560 and
was ELISA positive with a low optical density. In the Western blotting
analysis using the native HGE agent, B14 serum did not react with any
protein even at a serum dilution of 1:100 (Fig. 1). Furthermore, this
serum did not react with rP44 in the Western blotting analysis (data
not shown). From these results, we concluded that the antibody against
P44 proteins of HGE agent in this patient disappeared 110 days after
positive HGE culture.
Comparison of results of IFA and ELISA using EK-rP44.
The
results of IFA and ELISA using sera from patients and healthy
individuals were compared (Table 3).
Usually, a new assay is evaluated by comparison with another
serological assay or combination of assays, and relative sensitivity
and specificity are calculated by making the previous assay result the
standard. In the present study, however, false-positive cases in IFA
were observed and ELISA was more specific than IFA. In such a case, the
relative diagnostic sensitivity and specificity can be calculated by
making the new method the standard of comparison (15). The
relative diagnostic sensitivity and specificity of IFA, calculated by
this manner, were 100 and 97%, respectively. These results indicate that ELISA using EK-rP44 is as sensitive as IFA and more specific than
IFA. The correlation of the results of IFA titers and ODs of ELISA
using EK-rP44 is shown in Fig. 2. The rho
value calculated by Spearman's rank correlation is 0.740 and is
statistically significant (P < 0.001), indicating a
positive correlation between IFA titer and OD of EK-rP44 ELISA.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Correlation between IFA titers and ODs of ELISA by using
EK-rP44 as an antigen. Each circle represents one sample. The rho value
calculated by Spearman's rank correlation was 0.740 (P < 0.001) (n = 181).
|
|
Comparison of results of ELISAs using EK-rP44 and EK-rP44-2hv.
All IFA-negative sera were negative by ELISA using EK-rP44-2hv. Of 35 EK-rP44 ELISA-positive sera, 27 sera from 16 patients were positive by
EK-rP44-2hv ELISA. Three patients were negative by EK-rP44-2hv ELISA
but positive by EK-rP44 ELISA for two different times. The results of
ELISAs using EK-rP44 and EK-rP44-2hv are compared in Table
4. The relative diagnostic sensitivity
and specificity was calculated by making the results of EK-rP44 antigen the standard of comparison. The relative diagnostic sensitivity of the
EK-rP44-2hv antigen was 77% and specificity was 100%. These results
indicate that EK-rP44 antigen is more sensitive than EK-rP44-2hv antigen in detecting antibodies against the HGE agent in patients.
 |
DISCUSSION |
The 38- to 49-kDa proteins of the HGE agent have been shown to be
immunodominant antigens in human infection (13, 26, 38). IgG
antibodies against 44-kDa protein were detected in all culture-positive
and PCR-positive patients' sera (38, 39) and in seven of
nine acute-phase patients (1 week after onset of symptoms) and in 10 day sera of mice exposed to Ehrlichia-infected (NCH-1
strain) ticks (13). These proteins are encoded by the p44 multigene family (40). Recently, Zhi et al.
cloned several genes belong to this family (39, 40). Zhi et
al. demonstrated that Western blot analysis and dot immunoblot assay
using rP44 as antigen were as specific and sensitive as IFA
(39). Furthermore, dot immunoblot assay using a synthetic
oligopeptide specific to the hypervariable region, P44-2hv of one of
P44 proteins, P44-2, and convalescent sera from patients with HGE
demonstrated that antibody specific to P44-2hv was developed in these
patients (40). However, Western blotting analysis and dot
immunoblot assay are not convenient for automated testing of a large
number of clinical samples. We developed an ELISA system using a
recombinant P44 as antigen because ELISA is easily adapted to
automation, allowing rapid testing of a large number of patient samples
at a relatively low cost. There was significant positive correlation
between IFA titers and ODs of rP44 ELISA. Since another report of ELISA
using recombinant HGE-44 does not describe ODs (12), it is
difficult to compare that data with our data. Although this was not
examined in another ELISA study (12), preabsorption of
patient sera with E. coli components which might be present
in the purified recombinant protein is not required in our ELISA using
recombinant proteins. Because it may be important for diagnosis to
detect low-titer antibody in sera without false-positive results, we
used the serum dilution of 1:20. In another report of an ELISA using
recombinant HGE-44 fused with maltose binding protein, cutoff ELISA ODs
were chosen at 0.45 (1:160 serum dilution), 0.38 (1:320 serum
dilution), and 0.26 (1:640 serum dilution) (12). These
cutoff ODs are higher than our cutoff OD, especially considering the
serum dilution used. Since the OD ranges of positive sera were not
described and ODs of the E. coli control or maltose binding
protein alone were not shown in that study, it is difficult to
interpret the high background OD of that ELISA. This variation may be
due to the difference of HGE agent strains or 44-kDa protein genes
cloned or expression vectors used. Amino acid identities between P44 and HGE-44 and between P44-2 and HGE-44 are 75.3 and 80.2%,
respectively (40).
In our ELISA systems using EK-rP44 and EK-rP44-2, no sera from the
limited number of patients infected with B. burgdorferi, B. microti, or E. chaffeensis had positive
reactions. Although B. microti-infected patients' sera
reacted with rP44 without EK treatment, the reactivity disappeared
after treatment with EK or rP44. The exact reason for this
cross-reactivity is unknown. The rP44 used in the present experiments
was cloned in the pET-30a expression vector. This vector encodes some
affinity tags which are useful for assaying expression levels and
purifying proteins. EK treatment is able to separate the affinity tags
from the recombinant protein. B. microti-infected patients'
sera also reacted with recombinant rP30 of Ehrlichia canis
(data not shown), which was prepared by using the same vector system
(23). These results suggest that the false reactivity might
be directed to the affinity tag region. Another report of an ELISA
using rHGE-44 fused with maltose binding protein (12) did
not examine whether human babesial infection sera cross-react with the
fusion protein. B. burgdorferi, B. microti, and
the HGE agent are carried by the same tick vector, Ixodes
scapularis (28, 35). Simultaneous infections of
patients with these agents have been reported (7, 21).
Antibiotics effective for these microorganisms are different and it is
important to distinguish among these diseases. Treatment of rP44 by EK
had no effect on the results of HGE-ELISA. Therefore, an ELISA system using the EK-rP44 described here may be able to distinguish HGE from
human monocytic ehrlichiosis, babesiosis, and Lyme borreliosis.
The five sera, which were positive by IFA testing but negative by
ELISAs using EK-rP44 and EK-rP44-2hv, were further examined by Western
blotting analysis. Three sera from one patient and one healthy
individual reacted only with an approximately 70-kDa protein of the HGE
agent. Previously, Ijdo et al. reported that heat shock protein 70 (HSP70) of the HGE agent (an 80-kDa protein by their description) was
cross-reactive with B. burgdorferi HSP70 (14).
HSP70s of many microorganisms such as E. coli,
Mycobacterium tuberculosis, and Plasmodium
falciparum share common antigenicity. It has been identified as an
immunodominant antigen in these infections (30). Although we
did not determine whether the 70-kDa protein that reacted with the sera
was HSP70 of the HGE agent or not, it is possible that the protein is
HSP70. ELISA using EK-rP44 or EK-rP44-2hv could eliminate
false-positive reactions due to cross-reactions caused by common
antigens including HSP70 present in many microorganisms. One serum
reacted with a single 44-kDa band of the HGE agent but not with rP44 in
Western blot analysis. The rP44 used in the present study lacks
one-third of P44 C terminus (39). Because the HGE agent
expresses multiple P44 homologous proteins encoded by a polymorphic
multigene family (40), it is possible that this serum
reacted with one or more of these P44 homologous proteins distinct from
rP44. However, since P44 homologous genes have highly conserved
N-terminal regions (40), mouse polyclonal antibody against
rP44 strongly recognizes multiple 44- to 42-kDa proteins in six HGE
isolates (39), and sera from patients infected with the HGE
agent reacted with not only multiple P44s but also with other proteins
in Western blotting analysis using the purified HGE agent (13, 26,
38). Thus, it is unlikely that individuals infected with the HGE
agent develop an antibody against only a single band of the HGE agent.
Lastly, one serum collected more than 3 months after the first
sampling, at a time when the IFA titer was significantly decreased, did
not react with any proteins of the native HGE agent or rP44 in Western
blotting. The disappearance of antibody against the HGE agent after
recovery from disease has been reported (11, 26). We
speculate that the antibody against the HGE agent had disappeared in
this case and that the reactivity in IFA was considered false positive.
The rP44 used in this study is coded by the N-terminal conserved region
and a part of the hypervariable region of p44 homologous genes (39, 40). As one of the membrane proteins, this
protein is hydrophobic, thus relatively difficult to handle
(39). In contrast, rP44-2hv is encoded by hypervariable
region of the p44-2 gene and is hydrophilic (40),
thus easy to handle. However, the sensitivity of rP44-2 in ELISA was
lower than that of rP44. This means that the protein coded by conserved
regions of the p44 gene may be required for sensitive
detection of anti-HGE antibodies in patients. Alternatively, since
three patients were repeatedly positive with rP44 but negative with
rP44-2hv antigen, they may be infected with different strains of the
HGE agent which lack or do not express p44-2. Because of the
excellent specificity, objectiveness, and ease of the assay, this ELISA
system using EK-rP44 as antigen is expected to improve serodiagnosis of HGE.
 |
ACKNOWLEDGMENTS |
This work was supported by grants AI40934 and AI47407 from the
National Institutes of Health. T. Tajima is a recipient of a
scholarship from the Ministry of Education, Science, Sports and
Culture, Japan.
We appreciate Makoto Kawahara for providing negative control human sera
and Lily I. Kong for supplying B. microti-infected patients' sera. We also thank Hyung-Yong Kim for separating several patients' serum specimens and preparing monoclonal antibody.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, 1925 Coffey Rd., Columbus, OH 43210-1093. Phone: (614) 292-5661. Fax: (614) 292-6473. E-mail:
rikihisa.1{at}osu.edu.
 |
REFERENCES |
| 1.
|
Aguero-Rosenfeld, M. E.,
H. W. Horowitz,
G. P. Wormser,
D. F. McKenna,
J. Nowakowski,
J. Munoz, and J. S. Dumler.
1996.
Human granulocytic ehrlichiosis: a case series from a medical center in New York State.
Ann. Intern. Med.
125:904-908[Abstract/Free Full Text].
|
| 2.
|
Bakken, J. S.,
J. S. Dumler,
S. M. Chen,
M. R. Eckman,
L. L. van Etta, and D. H. Walker.
1994.
Human granulocytic ehrlichiosis in the upper Midwest United States: a new species emerging?
JAMA
272:212-218[Abstract].
|
| 3.
|
Bakken, J. S.,
J. Krueth,
C. Wilson-Nordskog,
R. L. Tilden,
K. Asanovich, and J. S. Dumler.
1996.
Clinical and laboratory characteristics of human granulocytic ehrlichiosis.
JAMA
275:199-205[Abstract].
|
| 4.
|
Brouqui, P.
1999.
Ehrlichiosis in Europe, p. 220-232.
In
D. Raoult, and P. Brouqui (ed.), Rickettsiae and rickettsial diseases at the turn of the third millenium. Elsevier, Paris, France.
|
| 5.
|
Chen, S.-M.,
J. S. Dumler,
J. S. Bakken, and D. H. Walker.
1994.
Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.
J. Clin. Microbiol.
32:589-595[Abstract/Free Full Text].
|
| 6.
|
Comer, J. A.,
W. L. Nicholson,
J. G. Olson, and J. E. Childs.
1999.
Serologic testing for human granulocytic ehrlichiosis at a national referral center.
J. Clin. Microbiol.
37:558-564[Abstract/Free Full Text].
|
| 7.
|
Duffy, J.,
M. R. Pittlekow,
C. P. Kolbert,
B. J. Rutledge, and D. H. Persing.
1997.
Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis.
Lancet
349:399[Medline].
|
| 8.
|
Dumler, J. S.,
K. M. Asanovich,
J. S. Bakken,
P. Richter,
R. Kimsey, and J. E. Madigan.
1995.
Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic ehrlichia.
J. Clin. Microbiol.
33:1098-1103[Abstract].
|
| 9.
|
Hardalo, C. J.,
V. Quagliarello, and J. S. Dumler.
1995.
Human granulocytic ehrlichiosis in Connecticut: report of a fatal case.
Clin. Infect. Dis.
21:910-914[Medline].
|
| 10.
|
Hechemy, K. E.,
H. L. Harris,
M. J. Duerr,
J. L. Benach, and C. B. Reimer.
1988.
Immunoglobulin G subclasses specific to Borrelia burgdorferi in patients with Lyme disease.
Ann. N. Y. Acad. Sci.
539:162-169[Medline].
|
| 11.
|
Horowitz, H. W.,
M. Aguero-Rosenfeld,
J. S. Dumler,
D. F. McKenna,
T.-C. Hsieh,
J. Wu,
I. Schwartz, and G. P. Wormser.
1998.
Reinfection with the agent of human granulocytic ehrlichiosis.
Ann. Intern. Med.
129:461-463[Free Full Text].
|
| 12.
|
Ijdo, J. W.,
C. Wu,
L. A. Magnarelli, and E. Fikrig.
1999.
Serodiagnosis of human granulocytic ehrlichiosis by a recombinant HGE-44-based enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
37:3540-3544[Abstract/Free Full Text].
|
| 13.
|
Ijdo, J. W.,
Y. Zhang,
E. Hodzic,
L. A. Magnarelli,
M. L. Wilson,
S. R. Telford III,
S. W. Barthold, and E. Fikrig.
1997.
The early humoral response in human granulocytic ehrlichiosis.
J. Infect. Dis.
176:687-692[Medline].
|
| 14.
|
Ijdo, J. W.,
Y. Zhang,
M. L. Anderson,
D. Goldberg, and E. Fikrig.
1998.
Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies.
Clin. Diagn. Lab. Immunol.
5:118-120[Abstract/Free Full Text].
|
| 15.
|
Jacobson, R. H.
1998.
Validation of serological assays for diagnosis of infectious diseases.
Rev. Sci. Tech. Off. Int. Epiz.
17:469-486.
|
| 16.
|
Kim, H.-Y., and Y. Rikihisa.
1998.
Characterization of monoclonal antibodies to the 44-kilodalton major outer membrane protein of the human granulocytic ehrlichiosis agent.
J. Clin. Microbiol.
36:3278-3284[Abstract/Free Full Text].
|
| 17.
|
Lotric-Furlan, S.,
M. Petrovec,
T. Avsic-Zupanc,
W. L. Nicholson,
J. W. Sumner,
J. E. Childs, and F. Strle.
1998.
Human ehrlichiosis in Central Europe.
Wien. Klin. Wochenschr.
110:894-897[Medline].
|
| 18.
|
Magnarelli, L. A.,
J. S. Dumler,
J. F. Anderson,
R. C. Johnson, and E. Fikrig.
1995.
Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera.
J. Clin. Microbiol.
33:3054-3057[Abstract].
|
| 19.
|
Magnarelli, L. A.,
J. W. Ijdo,
J. F. Anderson,
S. J. Padula,
R. A. Flavell, and E. Fikrig.
1998.
Human exposure to a granulocytic ehrlichia and other tick-borne agents in Connecticut.
J. Clin. Microbiol.
36:2823-2827[Abstract/Free Full Text].
|
| 20.
|
Mitchell, P. D.,
K. D. Reed, and J. M. Hofkes.
1996.
Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota.
J. Clin. Microbiol.
34:724-727[Abstract].
|
| 21.
|
Nadelman, R. B.,
H. W. Horowitz,
T.-C. Hsieh,
J. M. Wu,
M. E. Aguero-Rosenfeld,
I. Schwartz,
J. Nowakowski,
S. Varde, and G. P. Wormser.
1997.
Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis.
N. Engl. J. Med.
337:27-30[Free Full Text].
|
| 22.
|
Nicholson, W. L.,
J. A. Comer,
J. W. Sumner,
C. Gingrich-Baker,
R. T. Coughlin,
L. A. Magnarelli,
J. G. Olson, and J. E. Childs.
1997.
An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis.
J. Clin. Microbiol.
35:1510-1516[Abstract].
|
| 23.
|
Ohashi, N.,
A. Unver,
N. Zhi, and Y. Rikihisa.
1998.
Cloning and characterization of multigenes encoding the immunodominant 30-kilodalton major outer membrane proteins of Ehrlichia canis and application of the recombinant protein for serodiagnosis.
J. Clin. Microbiol.
36:2671-2680[Abstract/Free Full Text].
|
| 24.
|
Pancholi, P.,
C. P. Kolbert,
P. Mitchell,
K. D. Reed,
J. S. Dumler,
J. S. Bakken,
S. R. Telford III, and D. H. Persing.
1995.
Ixodes dammini as a potential vector of human granulocytic ehrlichiosis.
J. Infect. Dis.
172:1007-1012[Medline].
|
| 25.
|
Petrovec, M.,
S. L. Furlan,
T. A. Zupanc,
F. Strle,
P. Brouqui,
V. Roux, and J. S. Dumler.
1997.
Human disease in Europe caused by a granulocytic Ehrlichia species.
J. Clin. Microbiol.
35:1556-1559[Abstract].
|
| 26.
|
Ravyn, M. D.,
J. L. Goodman,
C. B. Kodner,
D. K. Westad,
L. A. Coleman,
S. M. Engstrom,
C. M. Nelson, and R. C. Johnson.
1998.
Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates.
J. Clin. Microbiol.
36:1480-1488[Abstract/Free Full Text].
|
| 27.
|
Rikihisa, Y.,
N. Zhi,
G. P. Wormser,
B. Wen,
H. W. Horowitz, and K. E. Hechemy.
1997.
Ultrastructural and antigenic characterization of a granulocytic ehrlichiosis agent directly isolated and stably cultivated from a patient in New York State.
J. Infect. Dis.
175:210-213[Medline].
|
| 28.
|
Schauber, E. M.,
S. J. Gertz,
W. T. Maple, and R. S. Ostfeld.
1998.
Coinfection of blacklegged ticks (Acari: Ixodidae) in Dutchess County, New York, with the agent of Lyme disease and human granulocytic ehrlichiosis.
J. Med. Entomol.
35:901-903[Medline].
|
| 29.
|
Schwartz, I.,
D. Fish, and T. J. Daniels.
1997.
Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease.
N. Engl. J. Med.
337:49-50[Free Full Text].
|
| 30.
|
Shinnick, T. M.
1991.
Heat shock proteins as antigens of bacterial and parasitic pathogens.
Curr. Top. Microbiol. Immunol.
167:145-160[Medline].
|
| 31.
|
Sumner, J. W.,
W. L. Nicholson, and R. F. Massung.
1997.
PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of Ehrlichia species.
J. Clin. Microbiol.
35:2087-2092[Abstract].
|
| 32.
|
Telford, S. R., III,
T. J. Lepore,
P. Snow,
C. K. Warner, and J. E. Dawson.
1995.
Human granulocytic ehrlichiosis in Massachusetts.
Ann. Intern. Med.
123:277-279[Free Full Text].
|
| 33.
|
Unver, A.,
Y. Rikihisa,
N. Ohashi,
L. C. Cullman,
R. Buller, and G. A. Storch.
1999.
Western and dot blotting analyses of Ehrlichia chaffeensis indirect fluorescent-antibody assay-positive and -negative human sera by using native and recombinant E. chaffeensis and E. canis antigens.
J. Clin. Microbiol.
37:3888-3895[Abstract/Free Full Text].
|
| 34.
|
Van Dobbenburgh, A.,
A. P. Van Dam, and E. Fikrig.
1999.
Human granulocytic ehrlichiosis in Western Europe.
N. Engl. J. Med.
340:1214-1216[Free Full Text].
|
| 35.
|
Varde, S.,
J. Beckley, and I. Schwartz.
1998.
Prevalence of tick-borne pathogens in Ixodes scapularis in a rural New Jersey County.
Emerg. Infect. Dis.
4:97-99[Medline].
|
| 36.
|
Wormser, G.,
D. Mckenna,
M. Aguero-Rosenfeld, et al.
1995.
Human granulocytic ehrlichiosis New York.
Morb. Mortal. Wkly. Rep.
44:593-595[Medline].
|
| 37.
|
Yeh, M.-T.,
T. N. Mather,
R. T. Coughlin,
C. Gingrich-Baker,
J. W. Sumner, and R. F. Massung.
1997.
Serologic and molecular detection of granulocytic ehrlichiosis in Rhode Island.
J. Clin. Microbiol.
35:944-947[Abstract].
|
| 38.
|
Zhi, N.,
Y. Rikihisa,
H. Y. Kim,
G. P. Wormser, and H. W. Horowitz.
1997.
Comparison of major antigenic proteins of six strains of the human granulocytic ehrlichiosis agent by Western immunoblot analysis.
J. Clin. Microbiol.
35:2606-2611[Abstract].
|
| 39.
|
Zhi, N.,
N. Ohashi,
Y. Rikihisa,
H. W. Horowitz,
G. P. Wormser, and K. Hechemy.
1998.
Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis.
J. Clin. Microbiol.
36:1666-1673[Abstract/Free Full Text].
|
| 40.
|
Zhi, N.,
N. Ohashi, and Y. Rikihisa.
1999.
Multiple p44 genes encoding major outer membrane proteins are expressed in the human granulocytic ehrlichiosis agent.
J. Biol. Chem.
274:17828-17836[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 652-657, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhi, N., Ohashi, N., Tajima, T., Mott, J., Stich, R. W., Grover, D., Telford III, S. R., Lin, Q., Rikihisa, Y.
(2002). Transcript Heterogeneity of the p44 Multigene Family in a Human Granulocytic Ehrlichiosis Agent Transmitted by Ticks. Infect. Immun.
70: 1175-1184
[Abstract]
[Full Text]
-
Unver, A., Felek, S., Paddock, C. D., Zhi, N., Horowitz, H. W., Wormser, G. P., Cullman, L. C., Rikihisa, Y.
(2001). Western Blot Analysis of Sera Reactive to Human Monocytic Ehrlichiosis and Human Granulocytic Ehrlichiosis Agents. J. Clin. Microbiol.
39: 3982-3986
[Abstract]
[Full Text]
-
Lodes, M. J., Mohamath, R., Reynolds, L. D., McNeill, P., Kolbert, C. P., Bruinsma, E. S., Benson, D. R., Hofmeister, E., Reed, S. G., Houghton, R. L., Persing, D. H.
(2001). Serodiagnosis of Human Granulocytic Ehrlichiosis by Using Novel Combinations of Immunoreactive Recombinant Proteins. J. Clin. Microbiol.
39: 2466-2476
[Abstract]
[Full Text]